Q/C Technologies (QCLS) Drops -44% in the Past Month on Persistent Dilution Worries

Key Takeaways

• Q/C Technologies (QCLS) shares fell approximately 44% over the last 30 days, sliding from about $0.54 to roughly $0.30.
• The decline extends a broader multi-month downtrend: the stock is down roughly 89% over the trailing three months from about $2.86 in mid-August.
• QCLS remains a pre-revenue, clinical-stage pharmaceutical and optical-computing company with no product sales and limited near-term commercial catalysts.
• Ongoing share dilution, an estimated cash runway of roughly a year, and an active shelf registration continue to weigh on investor sentiment.
• The September 30 research collaboration with Sandia National Laboratories was met with selling, as it carried no disclosed funding or commercial terms.
• A mid-September leadership and advisory shuffle, including the termination of consulting ties to entities associated with Martin Shkreli, added to volatility.
• For additional details, explore QCLS price targets, earnings, and forecasts pages.

Company Background for Q/C Technologies (QCLS)

Q/C Technologies, Inc. is a clinical-stage pharmaceutical company that has expanded into computing technology. Formerly known as TNF Pharmaceuticals, Inc., and before that MyMD Pharmaceuticals, Inc., the company adopted its current name and the QCLS ticker in September 2025. It operates through two segments. The Pharmaceuticals segment is developing Isomyosamine, a small molecule targeting the immunometabolic system for autoimmune-related conditions, and Supera-CBD, a synthetic analog of cannabidiol. The Computing Technology segment is focused on optical, or photonic, processing units intended for AI inference and blockchain infrastructure.

The company is pre-revenue, meaning it has generated no product sales, and funds operations primarily through capital raises. With a market capitalization of only a few million dollars and a 52-week range spanning roughly $0.30 to $8.17, QCLS trades as a speculative micro-cap whose valuation is driven more by narrative and financing events than by fundamental earnings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Stock Performance for Q/C Technologies (QCLS)

Over the last 30 days, QCLS shares declined approximately 44%, falling from a closing price of about $0.54 in mid-October to roughly $0.30 in mid-November. The move was largely one-directional, with periodic intraday bounces that did not hold.

The longer-term picture is even weaker. Over the trailing three months, the stock fell roughly 89% from about $2.86 in mid-August, and it sits far below its 52-week high of $8.17 reached earlier in 2026. This persistent decline reflects a sustained lack of buying support rather than a single isolated event.

Factors Behind the 30-Day Decline

Several verified factors contributed to the recent slide. The company remains pre-revenue, with no product sales and an accumulated deficit in the nine figures, which leaves the stock highly sensitive to financing and dilution concerns. QCLS has an active shelf registration and a history of share issuance, and market data services track its dilution risk as elevated.

The September 30 announcement of a research collaboration with Sandia National Laboratories' Center for Integrated Nanotechnologies was intended as a credibility signal for the optical processing unit initiative, but the stock declined on the news because the arrangement included no disclosed funding, exclusivity, or commercial terms. Separately, in mid-September the company terminated consulting agreements with Chelsea Voss and Ocean Avenue Holdings, an entity affiliated with Martin Shkreli, and Ms. Voss resigned from the board, adding to investor uncertainty around leadership and strategy.

Broader Quarterly Trends and Strategic Shifts

The quarterly decline reflects a broader loss of confidence in the company's strategic pivot. After renaming and re-tickering in September 2025 to pursue "quantum-class" photonic computing, QCLS signed an exclusive license for LightSolver laser-based processing units aimed at cryptocurrency applications. That arrangement was terminated in June 2026, with the company recording a multi-million-dollar impairment and pivoting again toward a proprietary optical processing unit for AI inference.

Throughout the quarter, investors weighed a cash balance in the low double-digit millions against an annual cash burn of a similar magnitude, implying a runway of roughly a year absent new capital. The combination of zero revenue, repeated strategic shifts, and heavy share dilution has kept downward pressure on the stock even as the company announced new technical hires and a relocated San Francisco headquarters.

What to Watch Going Forward for Q/C Technologies (QCLS)

Investors monitoring QCLS should focus on several factors. The most important is the company's ability to raise additional capital without further diluting common shareholders, given its limited cash runway. Progress, or lack thereof, on the optical processing unit initiative and any follow-up to the Sandia collaboration will also matter. Quarterly filings, which have repeatedly highlighted going-concern and dilution risks, and any changes to the capital structure or listing compliance status, are key events to track. As always, these are risk factors to monitor, not a basis for specific investment decisions.

Using Tickeron AI Tools in My Analysis

In my own research, I often rely on Tickeron’s AI Trading Bots to test rules-based strategies across volatile micro-caps. The platform provides a range of automated approaches with clear performance metrics, which helps me evaluate signals without building every model from scratch. This approach adds another layer of perspective when reviewing names like QCLS.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Dem Sem|Expert

Notable companies

Industry description

Market Cap

High and low price notable news

Volume